We are live on ! Find out more
CHB

Global X China Biotech Innovation ETF
CHB

Delisted

CHB was delisted on the 16th of February, 2024.

Back to rankings

3 hedge funds and large institutions have $278K invested in Global X China Biotech Innovation ETF in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

797% more capital invested

Capital invested by funds: $31K → $278K (+$247K)

200% more funds holding

Funds holding: 1 → 3 (+2)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+2
Holders Change %
+200%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$268K
2
BBPWM
Blue Bell Private Wealth Management
Pennsylvania
+$4.6K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2.85K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$249K +$268K +17,456 New
UBS Group
2
UBS Group
Switzerland
$25K -$2.85K -186 -10%
BBPWM
3
Blue Bell Private Wealth Management
Pennsylvania
$4K +$4.6K +300 New

CHB Hedge Fund Activity: Q4 2021 in Review

3 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q4 2021, worth a combined $278K — up 797% from $31K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CHB positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $268K. The largest seller was UBS Group, cutting an estimated $2.85K.

  • 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q4 2021, up from 1 in Q3 2021.
  • Funds reported $278K of Global X China Biotech Innovation ETF stock for Q4 2021, up 797% quarter-over-quarter.
  • 2 funds opened new Global X China Biotech Innovation ETF positions in Q4 2021 and 0 closed out, a net change of +2 holders.
  • The largest Global X China Biotech Innovation ETF buyer in Q4 2021 was Jane Street, an estimated $268K added.
  • The largest Global X China Biotech Innovation ETF seller in Q4 2021 was UBS Group, an estimated $2.85K sold.

Based on aggregated 13F filings for Q4 2021.